Prosecution Insights
Last updated: May 29, 2026

Vor Biopharma Inc.

5 pending office actions • 5 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days

Portfolio Summary

5
Total Pending OAs
5
Non-Final OAs
0
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 5 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

3
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
2
Due later

Deadline Fire Line

Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 5 of the docket's apps have a known mailing date.

-30dToday30d60d90d120d
Overdue (3)Due later (2)

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (20%)
2
Medium (40%)
1
Easy (20%)
1
Unknown (20%)

Rejection Statute Mix

BucketCases
§101 only1 (20%)
§103 only1 (20%)
§102 only1 (20%)
Double-patenting only1 (20%)
No statute on record1 (20%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

5
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

50 h
Manual time on pending OAs
10 h
Time saved (low, 20%)
18 h
Time saved (mid, 35%)
0.4 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
JOHANSEN, PETER N. 1 60.0% +23.8%
BUTTICE, AUDREY L 1 45.8% +21.5%
GOMEZ RODRIGUEZ, JULIO WASHINGTON 1 45.8% +50.0%
SULLIVAN, DENNIS JOHN 1 61.0% +49.9%
SU-TOBON, QIWEN NMN 1

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
17638607 COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION SULLIVAN, DENNIS JOHN 56d overdue

Interview Candidates (4)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.

App #TitleExaminerDue in
18023548 COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION GOMEZ RODRIGUEZ, JULIO WASHINGTON 98d overdue
17638607 COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION SULLIVAN, DENNIS JOHN 56d overdue
18269633 COMPOSITIONS AND METHODS FOR CD34 GENE MODIFICATION BUTTICE, AUDREY L 76d
18620496 COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC PROTEINS JOHANSEN, PETER N. 85d

Top Art Units

Art UnitApps
1644 1
1647 1
1637 1
1642 1
1636 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18620496 COMPOSITIONS AND METHODS FOR INHIBITION OF LINEAGE SPECIFIC PROTEINS JOHANSEN, PETER N. 1644 DP Non-Final OA 85d Pending Mar 28, 2024
18269633 COMPOSITIONS AND METHODS FOR CD34 GENE MODIFICATION BUTTICE, AUDREY L 1647 §103 Non-Final OA 76d Pending Jun 26, 2023
18023548 COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION GOMEZ RODRIGUEZ, JULIO WASHINGTON 1637 Other Non-Final OA 98d overdue Pending Feb 27, 2023
17638607 COMPOSITIONS AND METHODS FOR CLL1 MODIFICATION SULLIVAN, DENNIS JOHN 1642 §101 Non-Final OA 56d overdue Pending Feb 25, 2022
17613387 COMPOSITIONS AND METHODS FOR CD33 MODIFICATION SU-TOBON, QIWEN NMN 1636 §102 Non-Final OA 111d overdue Pending Nov 22, 2021

Managing Vor Biopharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month